11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Screening, Cloning and Expression of Active Streptokinase from an Iranian Isolate of S.equisimilis Group C in E. coli

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction: Streptokinase (SK) is a fibrinolytic protein secreted by β-hemolytic streptococci (βHS) groups A, C and G. Due to its importance as a thrombolytic drug, national screening programs in different countries for isolation of βHS and especially SK-producing group C (GCS) strains have been conducted. Herein, we provide data of the first screening study on βHS isolates in Iran for the aim of recombinant SK (rSK) production from a local strain.

          Materials and methods: 252 streptococcal samples were collected and characterized using microbial/biochemical assays. The GCS strains were serologically confirmed. Activity of GCS supernatant cultures was determined by caseinolytic assay in comparison with the standard strain GCS9542. The SK gene of the highest producer strain was selected for production of rSK in E.coli system. The rSKs activities were determined using chromogenic assay.

          Results: βHS were detected in 75 of the collected specimens (29.4%) including groups A (25.8%), C (3.6%) and G (0.4%). Analyses by SDS-PAGE and Western blotting indicated the proper expression of 47 kDa rSK proteins in E. coli for SK genes which were cloned from both the selected (GCS-87) and standard (GCS-9542) strains with the yields of 0.53 and 0.59 mg/ml (of the purified protein), respectively. The calculated activity for rSK 87 was around 90% of rSK9542 activity (0.18x105 IU/mg v/s 0.21x105 IU/mg).

          Conclusion: Results of the present study for the first time provided the possibility of producing rSK from a local and native source with comparable yields and activities similar to the standard strain.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Book: not found

          The Condensed Protocols from Molecular Cloning : A Laboratory Manual

          The Condensed Protocols From Molecular Cloning: A Laboratory Manualis a single–volume adaptation of the three–volume third edition of Molecular Cloning: A Laboratory Manual.This condensed book contains only the step–by–step portions of the protocols, accompanied by selected appendices from the world's best–selling manual of molecular biology techniques. Each protocol is cross–referenced to the appropriate pages in the original manual. This affordable companion volume, designed for bench use, offers individual investigators the opportunity to have their own personal collection of short protocols from the essential Molecular Cloning.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Streptokinase--a clinically useful thrombolytic agent.

            A failure of hemostasis and consequent formation of blood clots in the circulatory system can produce severe outcomes such as stroke and myocardial infraction. Pathological development of blood clots requires clinical intervention with fibrinolytic agents such as urokinase, tissue plasminogen activator and streptokinase. This review deals with streptokinase as a clinically important and cost-effective plasminogen activator. The aspects discussed include: the mode of action; the structure and structure-function relationships; the structural modifications for improving functionality; recombinant streptokinase; microbial production; and recovery of this protein from crude broths.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.

              (1990)
              A multicentre, randomised, open trial with a 2 x 2 factorial design was conducted to compare the benefits and risks of two thrombolytic agents, streptokinase (SK, 1.5 MU infused intravenously over 30-60 min) and alteplase (tPA, 100 mg infused intravenously over 3 h) in patients with acute myocardial infarction admitted to coronary care units within 6 h from onset of symptoms. The patients were also randomised to receive heparin (12,500 U subcutaneously twice daily until discharge from hospital, starting 12 h after beginning the tPA or SK infusion) or usual therapy. All patients without specific contraindications were given atenolol (5-10 mg iv) and aspirin (300-325 mg a day). The end-point of the study was the combined estimate of death plus severe left ventricular damage. 12,490 patients were randomised to four treatment groups (SK alone, SK plus heparin, tPA alone, tPA plus heparin). No specific differences between the two thrombolytic agents were detected as regards the combined end-point (tPA 23.1%; SK 22.5%; relative risk 1.04, 95% Cl 0.95-1.13), nor after the addition of heparin to the aspirin treatment (hep 22.7%, no hep 22.9%; RR 0.99, 95% Cl 0.91-1.08). The outcome of patients allocated to the four treatment groups was similar with respect to baseline risk factors such as age, Killip class, hours from onset of symptoms, and site and type of infarct. The rates of major in-hospital cardiac complications (reinfarction, post-infarction angina) were also similar. The incidence of major bleeds was significantly higher in SK and heparin treated patients (respectively, tPA 0.5%, SK 1.0%, RR 0.57, 95% Cl 0.38-0.85; hep 1.0%, no hep 0.6%, RR 1.64, 95% Cl 1.09-2.45), whereas the overall incidence of stroke was similar in all groups. SK and tPA appear equally effective and safe for use in routine conditions of care, in all infarct patients who have no contraindications, with or without post-thrombolytic heparin treatment. The 8.8% hospital mortality of the study population (compared with approximately 13% in the control cohort of the GISSI-1 trial) indicates the beneficial impact of the proven acute treatments for AMI.
                Bookmark

                Author and article information

                Journal
                Iran J Basic Med Sci
                Iran J Basic Med Sci
                IJBMS
                Iranian Journal of Basic Medical Sciences
                Mashhad University of Medical Sciences (Mashhad, Iran )
                2008-3866
                2008-3874
                April 2013
                : 16
                : 4
                : 620-627
                Affiliations
                [1 ] Microbiology Department, Pasteur Institute of Iran, Tehran, Iran
                [2 ] Virology Department, Pasteur Institute of Iran, Tehran, Iran
                [3 ] Biochemistry Department, Pasteur Institute of Iran, Tehran, Iran
                [4 ] Hepatitis and AIDS Department, Pasteur Institute of Iran, Tehran, Iran
                Author notes
                [* ]Corresponding author: Farzin Roohvand, Virology Department, Pasteur institute of Iran, Tehran, Iran. Tel/Fax: +98 21 66496682; E-mail: Farzin.roohvand@gmail.com, rfarzin@pasteur.ac.ir and Mohammad Mehdi Aslani, Microbiology department, Pasteur Institute of Iran, Tehran, Iran, E-mail: mmaslani@yahoo.com
                [* ]Corresponding author: Farzin Roohvand, Virology Department, Pasteur institute of Iran, Tehran, Iran. Tel/Fax: +98 21 66496682; E-mail: Farzin.roohvand@gmail.com, rfarzin@pasteur.ac.ir and Mohammad Mehdi Aslani, Microbiology department, Pasteur Institute of Iran, Tehran, Iran, E-mail: mmaslani@yahoo.com
                Article
                ijbms-16-620
                3821881
                24250939
                35733c4c-0fc9-4cad-88af-15dde8326b86
                © 2013: Iranian Journal of Basic Medical Sciences

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License, ( http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 9 March 2012
                : 6 August 2012
                Categories
                Original Article

                gene expression,recombinant streptokinase,streptococcus

                Comments

                Comment on this article